###begin article-title 0
The impact of hyperactivity and leptin on recovery from anorexia nervosa
###end article-title 0
###begin title 1
Summary
###end title 1
###begin p 2
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
In anorexia nervosa (AN), hyperactivity is observed in about 80% of patients and has been associated with low leptin levels in the acute stage of AN and in anorexia animal models. To further understand the importance of this correlation in AN, we investigated the relationship between hypoleptinaemia and hyperactivity in AN patients longitudinally and assessed their predictive value for recovery.
###end p 2
###begin p 3
###xml 96 103 <span type="species:ncbi:9606">patient</span>
Body weight, activity levels, and serum leptin levels were assessed in adolescents and adult AN patient groups at the start and during treatment, up to a year. In the adolescent group, initial leptin and activity levels were correlated. This negative correlation changes over time into a positive correlation with physiological recovery. Treatment outcome in both groups could be predicted by initial BMI and leptin levels but not by activity levels. No major relationship of activity with the course of recovery was detected, suggesting that in contrast to the acute stage of the disease, leptin and activity levels during the recovery process are dissociated.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 130 148 130 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">Lucas et al., 1991</xref>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1999</xref>
###xml 156 177 156 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">Hoek and Hoeken, 2003</xref>
###xml 441 479 441 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">American Psychiatric Association, 1994</xref>
###xml 107 112 <span type="species:ncbi:9606">girls</span>
###xml 123 128 <span type="species:ncbi:9606">women</span>
Anorexia nervosa (AN) is a complex eating disorder of unknown etiology, which primarily affects adolescent girls and young women (Lucas et al., 1991, 1999; Hoek and Hoeken, 2003). It is characterized by aberrant patterns of eating behavior and weight regulation which result in weight loss and endocrine abnormalities such as amenorrhea, disturbances in attitude and perception about weight and shape, and an intense fear of gaining weight (American Psychiatric Association, 1994).
###end p 5
###begin p 6
###xml 132 150 132 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">Piran et al., 1985</xref>
###xml 152 175 152 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">Casper and Jabine, 1996</xref>
###xml 228 250 228 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">Hebebrand et al., 2003</xref>
###xml 670 682 670 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">Casper, 1998</xref>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2006</xref>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
Other symptoms, such as perfectionism, obsessive-compulsive behavior, and social anxiety are observed in many but not all patients (Piran et al., 1985; Casper and Jabine, 1996). In addition, a proportion of AN patients (31-80%, Hebebrand et al., 2003) displays abnormally high physical activity levels and overexercises. Almost all patients show a constant, agitated restlessness when they are emaciated but before they become lethargic in the final stages of starvation. The exact nature of hyperactivity in anorexia nervosa remains to be clarified. It appears that neurobiological factors and conscious attempts to burn calories in order to loose more weight coexist (Casper, 1998, 2006).
###end p 6
###begin p 7
###xml 107 137 107 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">Routtenberg and Kuznesof, 1967</xref>
###xml 139 155 139 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">Kas et al., 2003</xref>
###xml 214 225 214 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">Pirke, 1993</xref>
###xml 227 245 227 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">Exner et al., 2000</xref>
###xml 466 482 466 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">Kas et al., 2003</xref>
###xml 494 514 494 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">Gelegen et al., 2007</xref>
###xml 646 664 646 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">Exner et al., 2000</xref>
###xml 666 690 666 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">Hillebrand et al., 2005a</xref>
###xml 460 464 <span type="species:ncbi:10116">rats</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10116">rats</span>
Animal models mimicking AN weight loss and hyperactivity, such as the activity based anorexia (ABA) model (Routtenberg and Kuznesof, 1967; Kas et al., 2003) or the semistarvation induced hyperactivity (SIH) model (Pirke, 1993; Exner et al., 2000) have been helpful in the search for a possible biological drive or changes in physiological parameters that trigger food restriction and hyperactivity. Studies using these preclinical models showed that anorectic rats (Kas et al., 2003) and mice (Gelegen et al., 2007) have reduced plasma leptin levels and that treating food restricted rats with leptin suppresses the development of hyperactivity (Exner et al., 2000; Hillebrand et al., 2005a).
###end p 7
###begin p 8
###xml 65 83 65 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">Zhang et al., 1994</xref>
###xml 271 291 271 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">Moschos et al., 2002</xref>
###xml 352 370 352 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">Ahima et al., 1996</xref>
###xml 410 431 410 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">Calandra et al., 2003</xref>
###xml 649 668 649 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">Eckert et al., 1998</xref>
###xml 670 691 670 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">Holtkamp et al., 2004</xref>
###xml 693 715 693 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">Mantzoros et al., 2006</xref>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
###xml 486 494 <span type="species:ncbi:9606">patients</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
###xml 882 890 <span type="species:ncbi:9606">patients</span>
Leptin is an adipocyte secreted hormone, product of the ob gene (Zhang et al., 1994), which plays a pivotal role in starvation situations with regard to energy homeostasis as well as other physiological processes, including reproductive functioning (Cioffi et al., 1996; Moschos et al., 2002). Plasma leptin levels rapidly decrease during weight loss (Ahima et al., 1996) and are extremely low in AN patients (Calandra et al., 2003). However, leptin levels in recently weight recovered patients have been found to be higher than in BMI-matched controls, and are thought to contribute to difficulties with further weight restoration and maintenance (Eckert et al., 1998; Holtkamp et al., 2004; Mantzoros et al., 2006). Holtkamp et al. have shown that patients leptin levels are negatively correlated with motor restlessness scores (2003) and with physical activity in acutely ill AN patients (2006). Thus, pre-clinical and clinical observations suggest that hypoleptinemia is an important factor underlying excessive physical activity in AN. The meaning of these findings for recovery have however not been studied in detail to date.
###end p 8
###begin p 9
###xml 127 135 <span type="species:ncbi:9606">patients</span>
The objective of this study was to investigate the relationship between hyperactivity, serum leptin levels, and recovery in AN patients.
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Subjects
###end title 11
###begin p 12
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were included in the study after they and/or their parents gave informed consent. The sample was recruited in two specialized eating disorder treatment centers (clinics), one for adolescents 12-17 years (the University Medical Center Utrecht [UMCU], 31 subjects) and one for adults older than 17 years (Rintveld, 30 subjects). The clinical research protocol for this prospectively designed, cohort follow-up study was approved by the UMCU Ethics Review Committee.
###end p 12
###begin p 13
###xml 67 105 67 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">American Psychiatric Association, 1994</xref>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
Inclusion criteria were: (1) AN diagnosed according to the DSM-IV (American Psychiatric Association, 1994) on the basis of a structured interview using the Eating Disorders Examination (Cooper et al., 1989); (2) comorbidity restricted to depression or anxiety disorders; (3) secondary amenorrhea; (4) no use of steroid contraceptives; (5) no clinical history of concurrent illnesses. Sixty-one female patients were included, 24 of the AN purging type, 37 of the AN restricting type.
###end p 13
###begin title 14
Study design
###end title 14
###begin p 15
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
###xml 706 714 <span type="species:ncbi:9606">patients</span>
After initial psychiatric assessment, patients entered a structured treatment program aimed at restoration of the patient's weight, normalization of eating patterns, body image, anorectic cognitions and family and social functioning. Weight gain was targeted at 0.5-1.0 kg/week in accordance with clinical guidelines. Weight recovery was defined as a weight within the normal range for age (>SD -1.5 corresponding with a body mass index [BMI] of approximately 19 kg/m2 for adults) and target weight as the weight at which patients resumed a regular menstrual cycle, defined as three menstrual periods at three to five week intervals. Individual, group and family therapy techniques were used to change the patients' aberrant body perception and cognition.
###end p 15
###begin p 16
###xml 24 31 <span type="species:ncbi:9606">patient</span>
Data was collected from patient acceptance into the treatment program, in the acute stage of the illness, until the end point, defined as recovery (return of regular menses), or up to one year after begin of treatment.
###end p 16
###begin p 17
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 382 411 382 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">Van Buuren and Fredriks, 2001</xref>
Body weight was measured once a week. The degree of underweight was calculated using BMI (kg/m2) and BMI computed into z scores which describe the distance in SD from the mean BMI for that age (using a software program provided by the Netherlands Organization for Applied Scientific Research to account for differences in age) and to relate the data to Dutch population references (Van Buuren and Fredriks, 2001).
###end p 17
###begin p 18
Blood samples for hormonal analysis were obtained by venepuncture at admission and every two weeks thereafter at 4 pm, up to the maximum study period of one year.
###end p 18
###begin title 19
Activity measures
###end title 19
###begin p 20
###xml 222 245 222 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">Van Elburg et al., 2007</xref>
###xml 204 211 <span type="species:ncbi:9606">patient</span>
Physical activity levels were measured by trained nurses once a week. In an earlier study using actometer measurement as gold standard we established the reliability and validity of nurse observations of patient activity (Van Elburg et al., 2007). Nurses were instructed to observe activity, defined as the amount of motor restlessness (inability to sit still or moving arms or legs while seated, walking through the ward without reason), abnormal motor activity, and excessive exercise, and to score their observations on a visual analogue scale (0-10).
###end p 20
###begin title 21
Leptin assay
###end title 21
###begin p 22
###xml 109 114 <span type="species:ncbi:9606">Human</span>
Plasma samples were stored at -80degreesC prior to determination. Leptin was measured using a sensitive RIA (Human-Leptin-RIA sensitive, Mediagnost, Tubingen, Germany), intra-assay CV of 5%, inter-assay CV of 7.6%.
###end p 22
###begin title 23
Statistics
###end title 23
###begin p 24
###xml 75 83 <span type="species:ncbi:9606">patients</span>
At the study endpoint, follow-up data was collected on the basis of which, patients were divided into three groups according to their recovery stage: no weight recovery (NWR), weight recovery without resumption of menses (WR) and weight and cycle recovery (WCR). Data are presented as the mean +/- SD if distributed normally, otherwise as the median and range. Kruskal-Wallis tests were used if data were not normally distributed. In case data were normally distributed ANOVA was used. Linear multiple regression analysis (backward elimination) was also carried out to predict physical activity using BMI z scores and log 10 leptin levels as predictor variables. A p-value of <0.05 was considered to be statistically significant.
###end p 24
###begin p 25
###xml 504 505 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
To determine the associations of weight, leptin and physical activity levels with the rate of recovery as defined by the menstrual cycle at end point, univariate and multivariate Cox proportional hazards analyses were performed. This method of analysis estimates a linear regression model of parameters against the logarithm of the hazard (or instantaneous risk) of the menstrual cycle recovery during follow-up. Initial values of parameters were used as potential predictors. Parameters with univariate p<0.30 were candidate predictors for the multivariate model; backward elimination of parameters (with p<0.05 for inclusion) was used to determine the set of most predictive parameters. Because of potential differences in prognosis averages between the two treatment centers, the analysis was stratified by clinic. The analysis was first performed with initial values of weight, leptin and physical activity levels as predictors and subsequently with longitudinal values, using Cox regression with time-dependent covariates. A further analysis of longitudinal data focused on the evolvement of the association between leptin levels and activity levels during the course of treatment. A linear mixed model was used, predicting physical activity from log 10 leptin levels, follow-up time measured in weeks and final recovery status as predictor variables. A potential difference between the recovered and nonrecovered group in the evolvement of the association between leptin levels and activity levels over time was tested by an interaction of (log 10 leptin) *week* group.
###end p 25
###begin p 26
Statistical analysis was performed using SPSS forWindows (release 11.5, SPSS Inc., Chicago, IL) and S-plus software (MathSoft Inc., Seattle, WA, version 2000).
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 203 204 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 265 266 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 619 626 609 616 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</label>
###xml 626 928 616 914 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Demographics (mean &#177; SD) of 61 young women diagnosed with anorexia nervosa. Data are presented for the entire group, and separately for women presenting with no weight recovery (NWR), with weight recovery (WR) only and with weight &#177; cycle recovery (WCR) during the study period of maximum 12 months</p>
###xml 626 928 616 914 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Demographics (mean &#177; SD) of 61 young women diagnosed with anorexia nervosa. Data are presented for the entire group, and separately for women presenting with no weight recovery (NWR), with weight recovery (WR) only and with weight &#177; cycle recovery (WCR) during the study period of maximum 12 months</p></caption>
###xml 928 937 914 923 <th xmlns:xlink="http://www.w3.org/1999/xlink">Variables</th>
###xml 950 951 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 937 957 923 943 <th xmlns:xlink="http://www.w3.org/1999/xlink">Total group (<italic>n</italic> = 61)</th>
###xml 962 963 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 957 969 943 955 <th xmlns:xlink="http://www.w3.org/1999/xlink">NWR (<italic>n</italic> = 19)</th>
###xml 973 974 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 969 980 955 966 <th xmlns:xlink="http://www.w3.org/1999/xlink">WR (<italic>n</italic> = 18)</th>
###xml 985 986 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 980 992 966 978 <th xmlns:xlink="http://www.w3.org/1999/xlink">WCR (<italic>n</italic> = 24)</th>
###xml 928 992 914 978 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Variables</th><th>Total group (<italic>n</italic> = 61)</th><th>NWR (<italic>n</italic> = 19)</th><th>WR (<italic>n</italic> = 18)</th><th>WCR (<italic>n</italic> = 24)</th></tr>
###xml 928 992 914 978 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Variables</th><th>Total group (<italic>n</italic> = 61)</th><th>NWR (<italic>n</italic> = 19)</th><th>WR (<italic>n</italic> = 18)</th><th>WCR (<italic>n</italic> = 24)</th></tr></thead>
###xml 992 1003 978 989 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 1003 1015 989 999 <td xmlns:xlink="http://www.w3.org/1999/xlink">18.2 &#177; 3.1</td>
###xml 1015 1027 999 1009 <td xmlns:xlink="http://www.w3.org/1999/xlink">17.3 &#177; 2.2</td>
###xml 1027 1039 1009 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.9 &#177; 3.2</td>
###xml 1039 1065 1019 1043 <td xmlns:xlink="http://www.w3.org/1999/xlink">19.8 &#177; 3.0* vs. NWR + WR</td>
###xml 992 1065 978 1043 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>18.2 &#177; 3.1</td><td>17.3 &#177; 2.2</td><td>16.9 &#177; 3.2</td><td>19.8 &#177; 3.0* vs. NWR + WR</td></tr>
###xml 1065 1079 1043 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink">Weeks in study</td>
###xml 1079 1092 1057 1068 <td xmlns:xlink="http://www.w3.org/1999/xlink">33.5 &#177; 11.4</td>
###xml 1092 1105 1068 1079 <td xmlns:xlink="http://www.w3.org/1999/xlink">32.8 &#177; 11.6</td>
###xml 1105 1118 1079 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink">36.9 &#177; 14.0</td>
###xml 1118 1130 1090 1100 <td xmlns:xlink="http://www.w3.org/1999/xlink">31.6 &#177; 8.8</td>
###xml 1065 1130 1043 1100 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Weeks in study</td><td>33.5 &#177; 11.4</td><td>32.8 &#177; 11.6</td><td>36.9 &#177; 14.0</td><td>31.6 &#177; 8.8</td></tr>
###xml 1130 1158 1100 1128 <td xmlns:xlink="http://www.w3.org/1999/xlink">Bodyweight, initial z scores</td>
###xml 1158 1170 1128 1138 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3.8 &#177; 1.6</td>
###xml 1170 1182 1138 1148 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4.2 &#177; 1.9</td>
###xml 1182 1194 1148 1158 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3.2 &#177; 1.5</td>
###xml 1194 1206 1158 1168 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3.8 &#177; 1.2</td>
###xml 1130 1206 1100 1168 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Bodyweight, initial z scores</td><td>&#8722;3.8 &#177; 1.6</td><td>&#8722;4.2 &#177; 1.9</td><td>&#8722;3.2 &#177; 1.5</td><td>&#8722;3.8 &#177; 1.2</td></tr>
###xml 1206 1229 1168 1191 <td xmlns:xlink="http://www.w3.org/1999/xlink">Bodyweight end of study</td>
###xml 1229 1241 1191 1201 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1.3 &#177; 1.1</td>
###xml 1253 1254 1211 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1241 1267 1201 1225 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2.1 &#177; 0.8<sup>*</sup> vs. WCR + WR</td>
###xml 1267 1279 1225 1235 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.9 &#177; 0.5</td>
###xml 1279 1291 1235 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.9 &#177; 0.6</td>
###xml 1206 1291 1168 1245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Bodyweight end of study</td><td>&#8722;1.3 &#177; 1.1</td><td>&#8722;2.1 &#177; 0.8<sup>*</sup> vs. WCR + WR</td><td>&#8722;0.9 &#177; 0.5</td><td>&#8722;0.9 &#177; 0.6</td></tr>
###xml 1291 1310 1245 1264 <td xmlns:xlink="http://www.w3.org/1999/xlink">Amenorrhea (months)</td>
###xml 1310 1323 1264 1275 <td xmlns:xlink="http://www.w3.org/1999/xlink">24.4 &#177; 22.8</td>
###xml 1323 1336 1275 1286 <td xmlns:xlink="http://www.w3.org/1999/xlink">20.5 &#177; 13.5</td>
###xml 1336 1349 1286 1297 <td xmlns:xlink="http://www.w3.org/1999/xlink">30.0 &#177; 30.5</td>
###xml 1349 1362 1297 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink">23.9 &#177; 23.6</td>
###xml 1291 1362 1245 1308 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Amenorrhea (months)</td><td>24.4 &#177; 22.8</td><td>20.5 &#177; 13.5</td><td>30.0 &#177; 30.5</td><td>23.9 &#177; 23.6</td></tr>
###xml 1362 1387 1308 1329 <td xmlns:xlink="http://www.w3.org/1999/xlink">Initial leptin (&#181;g/l)</td>
###xml 1387 1401 1329 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.1 (0.5&#8211;13.3)</td>
###xml 1401 1414 1343 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.9 (0.7&#8211;8.6)</td>
###xml 1414 1427 1356 1369 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.5 (0.5&#8211;4.6)</td>
###xml 1427 1441 1369 1383 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.4 (0.7&#8211;13.3)</td>
###xml 1362 1441 1308 1383 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Initial leptin (&#181;g/l)</td><td>2.1 (0.5&#8211;13.3)</td><td>2.9 (0.7&#8211;8.6)</td><td>1.5 (0.5&#8211;4.6)</td><td>2.4 (0.7&#8211;13.3)</td></tr>
###xml 1441 1464 1383 1406 <td xmlns:xlink="http://www.w3.org/1999/xlink">AN restrictive type (%)</td>
###xml 1464 1466 1406 1408 <td xmlns:xlink="http://www.w3.org/1999/xlink">69</td>
###xml 1466 1468 1408 1410 <td xmlns:xlink="http://www.w3.org/1999/xlink">79</td>
###xml 1468 1470 1410 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink">72</td>
###xml 1470 1472 1412 1414 <td xmlns:xlink="http://www.w3.org/1999/xlink">58</td>
###xml 1441 1472 1383 1414 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AN restrictive type (%)</td><td>69</td><td>79</td><td>72</td><td>58</td></tr>
###xml 1472 1488 1414 1430 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neuroleptics (%)</td>
###xml 1488 1490 1430 1432 <td xmlns:xlink="http://www.w3.org/1999/xlink">57</td>
###xml 1490 1492 1432 1434 <td xmlns:xlink="http://www.w3.org/1999/xlink">47</td>
###xml 1492 1494 1434 1436 <td xmlns:xlink="http://www.w3.org/1999/xlink">55</td>
###xml 1494 1496 1436 1438 <td xmlns:xlink="http://www.w3.org/1999/xlink">58</td>
###xml 1472 1496 1414 1438 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Neuroleptics (%)</td><td>57</td><td>47</td><td>55</td><td>58</td></tr>
###xml 1496 1505 1438 1447 <td xmlns:xlink="http://www.w3.org/1999/xlink">SSRIs (%)</td>
###xml 1505 1507 1447 1449 <td xmlns:xlink="http://www.w3.org/1999/xlink">33</td>
###xml 1507 1509 1449 1451 <td xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 1509 1511 1451 1453 <td xmlns:xlink="http://www.w3.org/1999/xlink">22</td>
###xml 1511 1513 1453 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink">50</td>
###xml 1496 1513 1438 1455 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>SSRIs (%)</td><td>33</td><td>26</td><td>22</td><td>50</td></tr>
###xml 1513 1535 1455 1477 <td xmlns:xlink="http://www.w3.org/1999/xlink">Initial activity score</td>
###xml 1535 1548 1477 1488 <td xmlns:xlink="http://www.w3.org/1999/xlink">52.5 &#177; 26.9</td>
###xml 1548 1561 1488 1499 <td xmlns:xlink="http://www.w3.org/1999/xlink">49.1 &#177; 27.9</td>
###xml 1561 1574 1499 1510 <td xmlns:xlink="http://www.w3.org/1999/xlink">56.2 &#177; 24.9</td>
###xml 1574 1587 1510 1521 <td xmlns:xlink="http://www.w3.org/1999/xlink">52.4 &#177; 28.8</td>
###xml 1513 1587 1455 1521 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Initial activity score</td><td>52.5 &#177; 26.9</td><td>49.1 &#177; 27.9</td><td>56.2 &#177; 24.9</td><td>52.4 &#177; 28.8</td></tr>
###xml 992 1587 978 1521 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age (years)</td><td>18.2 &#177; 3.1</td><td>17.3 &#177; 2.2</td><td>16.9 &#177; 3.2</td><td>19.8 &#177; 3.0* vs. NWR + WR</td></tr><tr><td>Weeks in study</td><td>33.5 &#177; 11.4</td><td>32.8 &#177; 11.6</td><td>36.9 &#177; 14.0</td><td>31.6 &#177; 8.8</td></tr><tr><td>Bodyweight, initial z scores</td><td>&#8722;3.8 &#177; 1.6</td><td>&#8722;4.2 &#177; 1.9</td><td>&#8722;3.2 &#177; 1.5</td><td>&#8722;3.8 &#177; 1.2</td></tr><tr><td>Bodyweight end of study</td><td>&#8722;1.3 &#177; 1.1</td><td>&#8722;2.1 &#177; 0.8<sup>*</sup> vs. WCR + WR</td><td>&#8722;0.9 &#177; 0.5</td><td>&#8722;0.9 &#177; 0.6</td></tr><tr><td>Amenorrhea (months)</td><td>24.4 &#177; 22.8</td><td>20.5 &#177; 13.5</td><td>30.0 &#177; 30.5</td><td>23.9 &#177; 23.6</td></tr><tr><td>Initial leptin (&#181;g/l)</td><td>2.1 (0.5&#8211;13.3)</td><td>2.9 (0.7&#8211;8.6)</td><td>1.5 (0.5&#8211;4.6)</td><td>2.4 (0.7&#8211;13.3)</td></tr><tr><td>AN restrictive type (%)</td><td>69</td><td>79</td><td>72</td><td>58</td></tr><tr><td>Neuroleptics (%)</td><td>57</td><td>47</td><td>55</td><td>58</td></tr><tr><td>SSRIs (%)</td><td>33</td><td>26</td><td>22</td><td>50</td></tr><tr><td>Initial activity score</td><td>52.5 &#177; 26.9</td><td>49.1 &#177; 27.9</td><td>56.2 &#177; 24.9</td><td>52.4 &#177; 28.8</td></tr></tbody>
###xml 928 1587 914 1521 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Total group (<italic>n</italic> = 61)</th><th>NWR (<italic>n</italic> = 19)</th><th>WR (<italic>n</italic> = 18)</th><th>WCR (<italic>n</italic> = 24)</th></tr></thead><tbody><tr><td>Age (years)</td><td>18.2 &#177; 3.1</td><td>17.3 &#177; 2.2</td><td>16.9 &#177; 3.2</td><td>19.8 &#177; 3.0* vs. NWR + WR</td></tr><tr><td>Weeks in study</td><td>33.5 &#177; 11.4</td><td>32.8 &#177; 11.6</td><td>36.9 &#177; 14.0</td><td>31.6 &#177; 8.8</td></tr><tr><td>Bodyweight, initial z scores</td><td>&#8722;3.8 &#177; 1.6</td><td>&#8722;4.2 &#177; 1.9</td><td>&#8722;3.2 &#177; 1.5</td><td>&#8722;3.8 &#177; 1.2</td></tr><tr><td>Bodyweight end of study</td><td>&#8722;1.3 &#177; 1.1</td><td>&#8722;2.1 &#177; 0.8<sup>*</sup> vs. WCR + WR</td><td>&#8722;0.9 &#177; 0.5</td><td>&#8722;0.9 &#177; 0.6</td></tr><tr><td>Amenorrhea (months)</td><td>24.4 &#177; 22.8</td><td>20.5 &#177; 13.5</td><td>30.0 &#177; 30.5</td><td>23.9 &#177; 23.6</td></tr><tr><td>Initial leptin (&#181;g/l)</td><td>2.1 (0.5&#8211;13.3)</td><td>2.9 (0.7&#8211;8.6)</td><td>1.5 (0.5&#8211;4.6)</td><td>2.4 (0.7&#8211;13.3)</td></tr><tr><td>AN restrictive type (%)</td><td>69</td><td>79</td><td>72</td><td>58</td></tr><tr><td>Neuroleptics (%)</td><td>57</td><td>47</td><td>55</td><td>58</td></tr><tr><td>SSRIs (%)</td><td>33</td><td>26</td><td>22</td><td>50</td></tr><tr><td>Initial activity score</td><td>52.5 &#177; 26.9</td><td>49.1 &#177; 27.9</td><td>56.2 &#177; 24.9</td><td>52.4 &#177; 28.8</td></tr></tbody></table>
###xml 1587 1595 1521 1529 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">* p&lt;0.01</p>
###xml 1587 1595 1521 1529 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">* p&lt;0.01</p></table-wrap-foot>
###xml 619 1595 609 1529 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p textid="29">Demographics (mean &#177; SD) of 61 young women diagnosed with anorexia nervosa. Data are presented for the entire group, and separately for women presenting with no weight recovery (NWR), with weight recovery (WR) only and with weight &#177; cycle recovery (WCR) during the study period of maximum 12 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Total group (<italic>n</italic> = 61)</th><th>NWR (<italic>n</italic> = 19)</th><th>WR (<italic>n</italic> = 18)</th><th>WCR (<italic>n</italic> = 24)</th></tr></thead><tbody><tr><td>Age (years)</td><td>18.2 &#177; 3.1</td><td>17.3 &#177; 2.2</td><td>16.9 &#177; 3.2</td><td>19.8 &#177; 3.0* vs. NWR + WR</td></tr><tr><td>Weeks in study</td><td>33.5 &#177; 11.4</td><td>32.8 &#177; 11.6</td><td>36.9 &#177; 14.0</td><td>31.6 &#177; 8.8</td></tr><tr><td>Bodyweight, initial z scores</td><td>&#8722;3.8 &#177; 1.6</td><td>&#8722;4.2 &#177; 1.9</td><td>&#8722;3.2 &#177; 1.5</td><td>&#8722;3.8 &#177; 1.2</td></tr><tr><td>Bodyweight end of study</td><td>&#8722;1.3 &#177; 1.1</td><td>&#8722;2.1 &#177; 0.8<sup>*</sup> vs. WCR + WR</td><td>&#8722;0.9 &#177; 0.5</td><td>&#8722;0.9 &#177; 0.6</td></tr><tr><td>Amenorrhea (months)</td><td>24.4 &#177; 22.8</td><td>20.5 &#177; 13.5</td><td>30.0 &#177; 30.5</td><td>23.9 &#177; 23.6</td></tr><tr><td>Initial leptin (&#181;g/l)</td><td>2.1 (0.5&#8211;13.3)</td><td>2.9 (0.7&#8211;8.6)</td><td>1.5 (0.5&#8211;4.6)</td><td>2.4 (0.7&#8211;13.3)</td></tr><tr><td>AN restrictive type (%)</td><td>69</td><td>79</td><td>72</td><td>58</td></tr><tr><td>Neuroleptics (%)</td><td>57</td><td>47</td><td>55</td><td>58</td></tr><tr><td>SSRIs (%)</td><td>33</td><td>26</td><td>22</td><td>50</td></tr><tr><td>Initial activity score</td><td>52.5 &#177; 26.9</td><td>49.1 &#177; 27.9</td><td>56.2 &#177; 24.9</td><td>52.4 &#177; 28.8</td></tr></tbody></table><table-wrap-foot><p textid="30">* p&lt;0.01</p></table-wrap-foot></table-wrap>
###xml 26 33 <span type="species:ncbi:9606">patient</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
###xml 665 670 <span type="species:ncbi:9606">women</span>
###xml 764 769 <span type="species:ncbi:9606">women</span>
The mean age of the whole patient group was 18.2 +/- 3.1 (SD) years, 15.9 +/- 1.2 years for the adolescent group and 20.6 +/- 2.9 years for the adult group. Average BMI at admission was 15.4 +/- 1.3 kg/m2, which corresponds to a BMI z score of -3.8 +/- -1.6 (Table 1). Within the one year time frame of the study, 42 (69%) patients met the weight recovery objectives. Of them 24 (39% of the total, 57% of the weight recovered group) also recovered their menstrual cycles; 18 patients recovered in weight without the resumption of a menstrual cycle. Nineteen patients (31%) remained at a low weight throughout the year. Table 1Demographics (mean +/- SD) of 61 young women diagnosed with anorexia nervosa. Data are presented for the entire group, and separately for women presenting with no weight recovery (NWR), with weight recovery (WR) only and with weight +/- cycle recovery (WCR) during the study period of maximum 12 monthsVariablesTotal group (n = 61)NWR (n = 19)WR (n = 18)WCR (n = 24)Age (years)18.2 +/- 3.117.3 +/- 2.216.9 +/- 3.219.8 +/- 3.0* vs. NWR + WRWeeks in study33.5 +/- 11.432.8 +/- 11.636.9 +/- 14.031.6 +/- 8.8Bodyweight, initial z scores-3.8 +/- 1.6-4.2 +/- 1.9-3.2 +/- 1.5-3.8 +/- 1.2Bodyweight end of study-1.3 +/- 1.1-2.1 +/- 0.8* vs. WCR + WR-0.9 +/- 0.5-0.9 +/- 0.6Amenorrhea (months)24.4 +/- 22.820.5 +/- 13.530.0 +/- 30.523.9 +/- 23.6Initial leptin (microg/l)2.1 (0.5-13.3)2.9 (0.7-8.6)1.5 (0.5-4.6)2.4 (0.7-13.3)AN restrictive type (%)69797258Neuroleptics (%)57475558SSRIs (%)33262250Initial activity score52.5 +/- 26.949.1 +/- 27.956.2 +/- 24.952.4 +/- 28.8* p<0.01
###end p 28
###begin p 29
###xml 39 44 <span type="species:ncbi:9606">women</span>
###xml 138 143 <span type="species:ncbi:9606">women</span>
Demographics (mean +/- SD) of 61 young women diagnosed with anorexia nervosa. Data are presented for the entire group, and separately for women presenting with no weight recovery (NWR), with weight recovery (WR) only and with weight +/- cycle recovery (WCR) during the study period of maximum 12 months
###end p 29
###begin p 30
* p<0.01
###end p 30
###begin p 31
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 795 803 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">patients</span>
There were no significant differences among the three outcome groups in initial body weight, duration of illness (defined by duration of amenorrhea), duration of study participation, type of AN (restrictive or purging type), plasma leptin levels, nurse ratings of physical activity levels, amount of prescribed neuroleptics, or SSRIs (Table 1). Fourteen patients used olanzapine, 7 in each group (clinic) with dosages ranging from 5 to 15 mg/day, average dose 7.5 mg in both clinics. A difference in age was observed. The group that recovered in weight and resumed a menstrual cycle was significantly older than the non-recovered group, which result also corresponds with the clinic where they were treated. Rates of recovering weight and menstrual cycle differed in the two clinics: 16% of the patients in the adolescent group recovered versus 63% of the patients in the adult group.
###end p 31
###begin p 32
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 416 417 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 435 441 435 441 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1</label>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 736 737 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 745 746 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 775 776 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 441 782 441 782 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Scatter plot of initial log 10 serum leptin levels versus observed levels of levels of activity in two groups of patients with AN. Activity is defined as the amount of motor restlessness, abnormal motor activity and excessive exercise, as observed by nurses. <italic>p</italic> = 0.027 for the adolescent group (<italic>N</italic> = 31), <italic>p</italic> = 0.12 for the adult group (<italic>N</italic> = 30)</p>
###xml 441 782 441 782 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Scatter plot of initial log 10 serum leptin levels versus observed levels of levels of activity in two groups of patients with AN. Activity is defined as the amount of motor restlessness, abnormal motor activity and excessive exercise, as observed by nurses. <italic>p</italic> = 0.027 for the adolescent group (<italic>N</italic> = 31), <italic>p</italic> = 0.12 for the adult group (<italic>N</italic> = 30)</p></caption>
###xml 782 782 782 782 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2007_Article_740_Fig1" id="MO1"/>
###xml 435 782 435 782 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig. 1</label><caption><p textid="33">Scatter plot of initial log 10 serum leptin levels versus observed levels of levels of activity in two groups of patients with AN. Activity is defined as the amount of motor restlessness, abnormal motor activity and excessive exercise, as observed by nurses. <italic>p</italic> = 0.027 for the adolescent group (<italic>N</italic> = 31), <italic>p</italic> = 0.12 for the adult group (<italic>N</italic> = 30)</p></caption><graphic position="anchor" xlink:href="702_2007_Article_740_Fig1" id="MO1"/></fig>
###xml 221 228 <span type="species:ncbi:9606">patient</span>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
For the group as a whole, initial leptin levels did not correlate with nurse ratings of activity, the scatter plot showing a U-shape (p = 0.082). After stratification by clinic and adjusted for BMI z sore, the adolescent patient group showed a linear association between activity levels and log 10 serum leptin levels (partial correlation: -0.40, p = 0.027), whereas the adult group shows the U-shaped scatter plot, p = 0.12 (Fig. 1). Fig. 1Scatter plot of initial log 10 serum leptin levels versus observed levels of levels of activity in two groups of patients with AN. Activity is defined as the amount of motor restlessness, abnormal motor activity and excessive exercise, as observed by nurses. p = 0.027 for the adolescent group (N = 31), p = 0.12 for the adult group (N = 30)
###end p 32
###begin p 33
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 334 335 334 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Scatter plot of initial log 10 serum leptin levels versus observed levels of levels of activity in two groups of patients with AN. Activity is defined as the amount of motor restlessness, abnormal motor activity and excessive exercise, as observed by nurses. p = 0.027 for the adolescent group (N = 31), p = 0.12 for the adult group (N = 30)
###end p 33
###begin p 34
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 384 391 384 391 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 2</label>
###xml 391 496 391 496 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Association of initial BMI z scores, leptin, and activity levels with time to recovery of menstrual cycle</p>
###xml 391 496 391 496 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Association of initial BMI z scores, leptin, and activity levels with time to recovery of menstrual cycle</p></caption>
###xml 496 505 496 505 <th xmlns:xlink="http://www.w3.org/1999/xlink">Parameter</th>
###xml 516 517 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 505 523 505 523 <th xmlns:xlink="http://www.w3.org/1999/xlink">Univariate <italic>p</italic> value</th>
###xml 536 537 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 523 543 523 543 <th xmlns:xlink="http://www.w3.org/1999/xlink">Multivariate <italic>p</italic> value</th>
###xml 543 565 543 565 <th xmlns:xlink="http://www.w3.org/1999/xlink">Hazard ratio* (95% CI)</th>
###xml 496 565 496 565 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Parameter</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr>
###xml 496 565 496 565 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Parameter</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr></thead>
###xml 565 576 565 576 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI z score</td>
###xml 576 582 576 582 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0014</td>
###xml 582 586 582 586 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.15</td>
###xml 586 586 586 586 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 565 586 565 586 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI z score</td><td>0.0014</td><td>0.15</td><td/></tr>
###xml 586 598 586 598 <td xmlns:xlink="http://www.w3.org/1999/xlink">Leptin level</td>
###xml 598 605 598 605 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt; 0.001</td>
###xml 605 612 605 612 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt; 0.001</td>
###xml 612 628 612 628 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.97 (1.31&#8211;2.97)</td>
###xml 586 628 586 628 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Leptin level</td><td>&lt; 0.001</td><td>&lt; 0.001</td><td>1.97 (1.31&#8211;2.97)</td></tr>
###xml 628 642 628 642 <td xmlns:xlink="http://www.w3.org/1999/xlink">Activity level</td>
###xml 642 646 642 646 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.84</td>
###xml 646 650 646 650 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.96</td>
###xml 650 650 650 650 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 628 650 628 650 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Activity level</td><td>0.84</td><td>0.96</td><td/></tr>
###xml 565 650 565 650 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>BMI z score</td><td>0.0014</td><td>0.15</td><td/></tr><tr><td>Leptin level</td><td>&lt; 0.001</td><td>&lt; 0.001</td><td>1.97 (1.31&#8211;2.97)</td></tr><tr><td>Activity level</td><td>0.84</td><td>0.96</td><td/></tr></tbody>
###xml 496 650 496 650 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr></thead><tbody><tr><td>BMI z score</td><td>0.0014</td><td>0.15</td><td/></tr><tr><td>Leptin level</td><td>&lt; 0.001</td><td>&lt; 0.001</td><td>1.97 (1.31&#8211;2.97)</td></tr><tr><td>Activity level</td><td>0.84</td><td>0.96</td><td/></tr></tbody></table>
###xml 650 730 650 730 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">* The change in hazard when the parameter is increased by one standard deviation</p>
###xml 730 775 730 775 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Cox regression stratified by treatment center</p>
###xml 650 775 650 775 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">* The change in hazard when the parameter is increased by one standard deviation</p><p textid="37">Cox regression stratified by treatment center</p></table-wrap-foot>
###xml 384 775 384 775 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p textid="35">Association of initial BMI z scores, leptin, and activity levels with time to recovery of menstrual cycle</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr></thead><tbody><tr><td>BMI z score</td><td>0.0014</td><td>0.15</td><td/></tr><tr><td>Leptin level</td><td>&lt; 0.001</td><td>&lt; 0.001</td><td>1.97 (1.31&#8211;2.97)</td></tr><tr><td>Activity level</td><td>0.84</td><td>0.96</td><td/></tr></tbody></table><table-wrap-foot><p textid="36">* The change in hazard when the parameter is increased by one standard deviation</p><p textid="37">Cox regression stratified by treatment center</p></table-wrap-foot></table-wrap>
Next, we analyzed the predictive value of initial BMI z score, activity and plasma leptin levels on complete (weight and cycle) recovery. In a univariate analysis, initial leptin levels and initial BMI z scores predicted a favourable outcome, whereas initial activity levels showed no correlation. Multivariate analysis showed that leptin was the sole significant variable (Table 2). Table 2Association of initial BMI z scores, leptin, and activity levels with time to recovery of menstrual cycleParameterUnivariate p valueMultivariate p valueHazard ratio* (95% CI)BMI z score0.00140.15Leptin level< 0.001< 0.0011.97 (1.31-2.97)Activity level0.840.96* The change in hazard when the parameter is increased by one standard deviationCox regression stratified by treatment center
###end p 34
###begin p 35
Association of initial BMI z scores, leptin, and activity levels with time to recovery of menstrual cycle
###end p 35
###begin p 36
* The change in hazard when the parameter is increased by one standard deviation
###end p 36
###begin p 37
Cox regression stratified by treatment center
###end p 37
###begin p 38
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 583 584 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 681 682 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 706 707 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 729 736 729 736 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 3</label>
###xml 736 855 736 855 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Time-dependent analysis of the association of BMI z scores, leptin and activity levels with recovery of menstrual cycle</p>
###xml 736 855 736 855 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Time-dependent analysis of the association of BMI z scores, leptin and activity levels with recovery of menstrual cycle</p></caption>
###xml 865 866 865 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 855 872 855 872 <th xmlns:xlink="http://www.w3.org/1999/xlink">Parameter <italic>p</italic> value</th>
###xml 883 884 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 872 890 872 890 <th xmlns:xlink="http://www.w3.org/1999/xlink">Univariate <italic>p</italic> value</th>
###xml 903 904 903 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 890 910 890 910 <th xmlns:xlink="http://www.w3.org/1999/xlink">Multivariate <italic>p</italic> value</th>
###xml 910 932 910 932 <th xmlns:xlink="http://www.w3.org/1999/xlink">Hazard ratio* (95% CI)</th>
###xml 855 932 855 932 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Parameter <italic>p</italic> value</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr>
###xml 855 932 855 932 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Parameter <italic>p</italic> value</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr></thead>
###xml 932 943 932 943 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI z score</td>
###xml 943 950 943 950 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt; 0.001</td>
###xml 950 955 950 955 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.003</td>
###xml 955 968 955 968 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.1 (1.3&#8211;3.3)</td>
###xml 932 968 932 968 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI z score</td><td>&lt; 0.001</td><td>0.003</td><td>2.1 (1.3&#8211;3.3)</td></tr>
###xml 968 974 968 974 <td xmlns:xlink="http://www.w3.org/1999/xlink">Leptin</td>
###xml 974 981 974 981 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt; 0.001</td>
###xml 981 986 981 986 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.022</td>
###xml 986 1002 986 1002 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.12 (1.02&#8211;1.24)</td>
###xml 968 1002 968 1002 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Leptin</td><td>&lt; 0.001</td><td>0.022</td><td>1.12 (1.02&#8211;1.24)</td></tr>
###xml 1002 1010 1002 1010 <td xmlns:xlink="http://www.w3.org/1999/xlink">Activity</td>
###xml 1010 1013 1010 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9</td>
###xml 1013 1013 1013 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1013 1013 1013 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1002 1013 1002 1013 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Activity</td><td>0.9</td><td/><td/></tr>
###xml 932 1013 932 1013 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>BMI z score</td><td>&lt; 0.001</td><td>0.003</td><td>2.1 (1.3&#8211;3.3)</td></tr><tr><td>Leptin</td><td>&lt; 0.001</td><td>0.022</td><td>1.12 (1.02&#8211;1.24)</td></tr><tr><td>Activity</td><td>0.9</td><td/><td/></tr></tbody>
###xml 855 1013 855 1013 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Parameter <italic>p</italic> value</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr></thead><tbody><tr><td>BMI z score</td><td>&lt; 0.001</td><td>0.003</td><td>2.1 (1.3&#8211;3.3)</td></tr><tr><td>Leptin</td><td>&lt; 0.001</td><td>0.022</td><td>1.12 (1.02&#8211;1.24)</td></tr><tr><td>Activity</td><td>0.9</td><td/><td/></tr></tbody></table>
###xml 1013 1193 1013 1193 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">* Hazard ratio for standardised parameters, with 95% confidence interval. The hazard ratio represents the change in hazard when the parameter is increased by one standard deviation</p>
###xml 1013 1193 1013 1193 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">* Hazard ratio for standardised parameters, with 95% confidence interval. The hazard ratio represents the change in hazard when the parameter is increased by one standard deviation</p></table-wrap-foot>
###xml 729 1193 729 1193 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p textid="39">Time-dependent analysis of the association of BMI z scores, leptin and activity levels with recovery of menstrual cycle</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter <italic>p</italic> value</th><th>Univariate <italic>p</italic> value</th><th>Multivariate <italic>p</italic> value</th><th>Hazard ratio* (95% CI)</th></tr></thead><tbody><tr><td>BMI z score</td><td>&lt; 0.001</td><td>0.003</td><td>2.1 (1.3&#8211;3.3)</td></tr><tr><td>Leptin</td><td>&lt; 0.001</td><td>0.022</td><td>1.12 (1.02&#8211;1.24)</td></tr><tr><td>Activity</td><td>0.9</td><td/><td/></tr></tbody></table><table-wrap-foot><p textid="40">* Hazard ratio for standardised parameters, with 95% confidence interval. The hazard ratio represents the change in hazard when the parameter is increased by one standard deviation</p></table-wrap-foot></table-wrap>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
Analysis of the longitudinal data using a Cox model with time-dependent covariates showed leptin and BMI z score as main influences on recovery of menstrual cycle. Adding activity did not improve prediction in the model (Table 3). The linear mixed model analysis showed that the recovered (WCR) and non-recovered patients (WR and NWR) differed significantly in the way the relationship between leptin and physical activity changed during the treatment period (P = 0.016, test for interaction): the correlation between leptin and physical activity remained the same during treatment (r = -0.28) in the NWR and WR groups, whereas in the WCR group it changed from an initial value of r = -0.22 at 16 weeks to r = +0.58 at 52 weeks. Table 3Time-dependent analysis of the association of BMI z scores, leptin and activity levels with recovery of menstrual cycleParameter p valueUnivariate p valueMultivariate p valueHazard ratio* (95% CI)BMI z score< 0.0010.0032.1 (1.3-3.3)Leptin< 0.0010.0221.12 (1.02-1.24)Activity0.9* Hazard ratio for standardised parameters, with 95% confidence interval. The hazard ratio represents the change in hazard when the parameter is increased by one standard deviation
###end p 38
###begin p 39
Time-dependent analysis of the association of BMI z scores, leptin and activity levels with recovery of menstrual cycle
###end p 39
###begin p 40
* Hazard ratio for standardised parameters, with 95% confidence interval. The hazard ratio represents the change in hazard when the parameter is increased by one standard deviation
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 121 129 <span type="species:ncbi:9606">patients</span>
In this longitudinal study we measured body weight, plasma leptin levels, and activity levels in a clinical sample of AN patients during recovery.
###end p 42
###begin p 43
###xml 57 73 57 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">Kas et al., 2003</xref>
###xml 75 96 75 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">Holtkamp et al., 2003</xref>
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 203 210 <span type="species:ncbi:9606">patient</span>
We replicated the finding from animal and human studies (Kas et al., 2003; Holtkamp et al., 2003, 2006) that initial log 10 leptin levels and activity levels in the acute stage of the illness in a young patient population are correlated, and found a linear correlation in our adolescent age group. In our adult group we found a U shaped correlation between activity and plasma leptin levels, which suggests that hyperactivity is age-related. Over time however, physical activity did not predict outcome and no major relationship between physical activity levels and the course of recovery could be detected for neither the adolescent nor the adult group.
###end p 43
###begin p 44
###xml 12 27 12 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">Holtkamp (2003)</xref>
###xml 242 265 242 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">Van Elburg et al., 2007</xref>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 380 387 <span type="species:ncbi:9606">patient</span>
###xml 502 509 <span type="species:ncbi:9606">Patient</span>
Contrary to Holtkamp (2003) we rated activity during treatment and observed by nurses instead of relying on anamnestic reports of physical activity in the months before admission or during the acute stage of the illness. In an earlier study (Van Elburg et al., 2007) we showed that nurses can reliably rate physical activity levels of anorexia nervosa patients. Measurements of a patient's physical activity levels by nurses correlate with activity scores from actometers, the gold standard reference. Patient self-reports did not correlate with the actometer scores. In clinical practice a variety of methods has been used to evaluate hyperactivity, but based on our previous findings conclusions drawn from studies using self-report or expert report not based on observation should be considered only with caution.
###end p 44
###begin p 45
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
Once patients were divided into different outcome groups at the end of the study period differences in levels of physical activity and leptin were found, even though initial levels were not significantly different. Initial plasma leptin levels for all groups were clearly below normal values. Only the WCR-group reached average levels in the normal range at the end of the study period. WR patients clearly responded to treatment and recovered in weight, however, their subnormal leptin levels most probably did not permit them to recover at the level of the gonadal axis.
###end p 45
###begin p 46
###xml 17 35 17 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">Haupt et al., 2005</xref>
###xml 37 54 37 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">Wang et al., 2006</xref>
###xml 334 351 334 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">Wang et al., 2006</xref>
###xml 522 540 522 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">Haupt et al., 2005</xref>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
Several studies (Haupt et al., 2005; Wang et al., 2006) have discussed the relationship between leptin and the use of atypical antipsychotics such as olanzapine, so far only in normal weight schizophrenic or psychotic patients. The results show that olanzapine in the first weeks of treatment may cause a surge in circulating leptin (Wang et al., 2006) but that elevated plasma leptin levels in chronically treated patients with schizophrenia are strongly predicted by adiposity, similar to untreated healthy individuals (Haupt et al., 2005).
###end p 46
###begin p 47
###xml 21 38 21 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">Hillebrand, 2005b</xref>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2003</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
In a previous study (Hillebrand, 2005b), we demonstrated that olanzapine reduces activity levels in AN patients without affecting body weight and plasma leptin levels. In our current study, 57% of patients used antipsychotics (neuroleptics), which might have influenced the relationship between leptin and activity scores. However, Cox regression analysis with medication as predictor showed no correlation (univariate: neuroleptics: p = 0.6, SSRIs: p = 0.3). Holtkamp et al. (2003, 2006) unfortunately do not report use of neuroleptics in their study populations.
###end p 47
###begin p 48
###xml 70 76 <span type="species:ncbi:9606">humans</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 241 248 <span type="species:ncbi:9606">patient</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
In summary, our study replicates earlier findings in both rodents and humans that hypoleptinaemia and high physical activity levels are related in acutely ill AN patients of a young age, but we did not find the same relationship in an older patient group. The negative correlation between leptin and activity that exists in the acute phase of the illness changes over the course of 16 weeks to become a positive correlation in the second half of the treatment period, as a result of recovery. In the non recovered patients the negative correlation continues. Furthermore, our data indicate that plasma leptin level is a good predictor of recovery in AN, however, we could not detect any major relationship between physical activity levels and the course of recovery. The latter indicates that leptin and physical activity levels during the recovery process are, in contrast to the acute stage of the disease, dissociated. Further detailed assessment of this relationship is required to elaborate on these findings and their implications for clinical practice.
###end p 48
###begin title 49
Acknowledgement
###end title 49
###begin p 50
###xml 79 84 <span type="species:ncbi:499858">Snoek</span>
The authors wish to express their gratitude to the research assistants Maartje Snoek and Hanneke Hop for their help with the data collection. Claudia Mika is gratefully acknowledged for assistance with the radioimmunoassay.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
Role of leptin in the neuroendocrine response to fasting
###end article-title 52
###begin article-title 53
The role of leptin in the etiopathogenesis of anorexia nervosa and bulimia
###end article-title 53
###begin article-title 54
Behavioral activation and lack of concern, core symptoms of anorexia nervosa?
###end article-title 54
###begin article-title 55
The 'drive for activity' and "restlessness" in anorexia nervosa: potential pathways
###end article-title 55
###begin article-title 56
An eight-year follow-up: outcome from adolescent compared to adult onset anorexia nervosa
###end article-title 56
###begin article-title 57
Leptin in anorexia nervosa
###end article-title 57
###begin article-title 58
###xml 59 63 <span type="species:ncbi:10116">rats</span>
Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa
###end article-title 58
###begin article-title 59
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Difference in susceptibility to activity-based anorexia in two inbred strains of mice
###end article-title 59
###begin article-title 60
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
###end article-title 60
###begin article-title 61
Plasma leptin and adiposity during antipsychotic treatment of schizophrenia
###end article-title 61
###begin article-title 62
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 67 71 <span type="species:ncbi:10116">rats</span>
Hyperactivity in patients with anorexia nervosa and in semistarved rats: evidence for a pivotal role of hypoleptinemia
###end article-title 62
###begin article-title 63
Leptin treatment in activity-based anorexia
###end article-title 63
###begin article-title 64
###xml 40 44 <span type="species:ncbi:10116">rats</span>
Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?
###end article-title 64
###begin article-title 65
Review of the prevalence and incidence of eating disorders
###end article-title 65
###begin article-title 66
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa
###end article-title 66
###begin article-title 67
###xml 82 90 <span type="species:ncbi:9606">patients</span>
High serum leptin levels subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa
###end article-title 67
###begin article-title 68
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Physical activity and restlessness correlate with leptin levels in patients with adolescent anorexia nervosa
###end article-title 68
###begin article-title 69
Refinement of behavioural traits in animals for the genetic dissection of eating disorders
###end article-title 69
###begin article-title 70
50-Year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study
###end article-title 70
###begin article-title 71
The ups and downs of anorexia nervosa
###end article-title 71
###begin article-title 72
Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain
###end article-title 72
###begin article-title 73
Leptin and reproduction: a review
###end article-title 73
###begin article-title 74
Affective disturbances in eating disorders
###end article-title 74
###begin article-title 75
###xml 40 43 <span type="species:ncbi:10116">rat</span>
Starvation-induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes
###end article-title 75
###begin article-title 76
###xml 19 23 <span type="species:ncbi:10116">rats</span>
Self-starvation of rats living in activity wheels on a restricted feeding schedule
###end article-title 76
###begin article-title 77
Worm plot: a simple diagnostic device for modelling growth reference curves
###end article-title 77
###begin article-title 78
Rapid leptin elevation after initiation of olanzapine?
###end article-title 78
###begin article-title 79
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Positional cloning of the mouse obese gene and its human homologue
###end article-title 79

